Uvex Blue Light Blockers are the main glasses chosen in scientific studies to proof efficacy in improving various sleep measures. 
 
The Orange Lens features Spectrum Control Technology (SCT), which absorbs more than 98% of the blue light emitted from your laptop, computer, iPad etc in the light spectrum up to 540 nanometers.
 
These glasses can also help inhibit vision problems like cataracts and age-related macular degeneration. Uvex Skyper Blue Light Glasses offer exceptional comfort for optimal screen viewing. Features include a 3-position ratcheting lens inclination system, adjustable-length Duoflex comfort cushioned temples, a molded-in nose bridge and wrap-around uni-lens.
 
Scientific evidence:
"Out of the 24 publications focusing on sleep, there was substantial evidence for blue-blocking glasses being a successful intervention for reducing sleep onset latency in patients with sleep disorders, jet lag, or variable shift work schedules. Given the well-established biological mechanism and clinical research showing that blue-blocking glasses are effective for inducing sleep, they are a viable intervention to recommend to patients with insomnia or a delayed sleep phase." (https://pubmed.ncbi.nlm.nih.gov/34030534/)
"PIRS total scores, and Quality of Life, Distress, and Sleep Parameter subscales, were improved in amber vs. clear lenses condition (p-values <0.05). Reported wake-time was significantly delayed, and mean subjective total sleep time (TST), overall quality, and soundness of sleep were significantly higher (p-values <0.05) in amber vs. clear lenses condition over the 7-d intervention period. Actigraphic measures of TST only were significantly higher in amber vs. clear lenses condition (p=0.035). Wearing amber vs. clear lenses for 2-h preceding bedtime for 1 week improved sleep in individuals with insomnia symptoms. These findings have health relevance given the broad use of light-emitting devices before bedtime and prevalence of insomnia. Amber lenses represent a safe, affordable, and easily implemented therapeutic intervention for insomnia symptoms." (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703049/)